Compare Freshworks Inc (FRSH) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Tempus AI — how do they compare? Freshworks Inc trades at $13.75 (market cap $3.56B), while Tempus AI trades at $70.25 (market cap $12.58B). The key difference: Tempus AI is far larger — about 3.5× Freshworks Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Tempus AI for 22 Days on average.
| FRSH | TEM | |
|---|---|---|
Market Cap | $3.56B | $12.58B |
Volume | 9,066,454 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $13.92 | $99.28 |
52-Week Low | $6.88 | $41.55 |
Typical Hold Time | 39 Days | 22 Days |
Enterprise Value | $2.93B | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.60, down 1.16% today, with strong technical momentum showing bullish moving averages despite overbought RSI readings. The company achieved its first GAAP profitability in Q2 2026 with revenue growth of 16% year-over-year, while maintaining impressive gross margins of 84.96%. Recent developments include FedRAMP certification progress and leadership in Gartner's ITSM Magic Quadrant.
The outlook remains positive with analyst consensus at $14.60 target (7.4% upside) and balanced buy/hold ratings. Key opportunities include AI monetization and enterprise expansion, while risks involve competitive SaaS pressures and execution on growth targets. The stock presents a compelling value proposition with improving profitability metrics.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
